Targeting the intrinsically disordered structural ensemble of a-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Tóth, Gergely ^a,d   Gardai, Shyra J ^d   Zago, Wagner ^d   Bertoncini, Carlos W ^a,b   Cremades, Nunilo ^a   Roy, Susan L ^c   Tambe, Mitali A ^c   Rochet, Jean Christophe ^c   Galvagnion, Celine ^a   Skibinski, Gaia ^f,g   Finkbeiner, Steven ^f,g,h   Bova, Michael ^d   Regnstrom, Karin ^d   Chiou, San San ^d   Johnston, Jennifer ^d   Callaway, Kari ^d   Anderson, John P ^d   Jobling, Michael F ^d   Buell, Alexander K ^a   Yednock, Ted A ^d   Knowles, Tuomas P J ^a   Vendruscolo, Michele ^a   Christodoulou, John ^e   Dobson, Christopher M ^a   Schenk, Dale ^d   McConlogue, Lisa ^d   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^c PURDUE UNIVERSITY   (United States)

^d ELAN PHARMACEUTICALS   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^g Hellman Family Foundation Program in Alzheimer's Disease Research   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELN 484217; ELN 484228; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DISRUPTION; CELL VACUOLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FEMALE; INTRACELLULAR TRANSPORT; MICROGLIA; MOLECULAR MODEL; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PHAGOCYTOSIS; PROTEIN ANALYSIS; PROTEIN CONTENT; SYNAPSE;

ALPHA-SYNUCLEIN; ANIMALS; BINDING SITES; DOPAMINERGIC NEURONS; HUMANS; INTRINSICALLY DISORDERED PROTEINS; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NERVE DEGENERATION; PARKINSON DISEASE; PHAGOCYTES; SMALL MOLECULE LIBRARIES; SYNAPSES;

EID: 84895866256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087133     Document Type: Article

References (68)

1. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302: 819-822. (Pubitemid 37339614)
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
3. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. The New England journal of medicine 342: 1560-1567. (Pubitemid 30340501)
4. Schiesling C, Kieper N, Seidel K, Kruger R (2008) Review: Familial Parkinson's disease-genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathology and applied neurobiology 34: 255-271. (Pubitemid 351590874)
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047. (Pubitemid 27443610)
6. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841. (Pubitemid 37339619)
7. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, et al. (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68: 916-922. (Pubitemid 46568503)
8. Saiki S, Sato S, Hattori N (2012) Molecular pathogenesis of Parkinson's disease: update. Journal of neurology, neurosurgery, and psychiatry 83: 430-436.
9. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature genetics 41: 1308-1312.
10. Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nature reviews Molecular cell biology 6: 197-208. (Pubitemid 40314921)
11. Tompa P (2005) The interplay between structure and function in intrinsically unstructured proteins. FEBS letters 579: 3346-3354.
12. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366. (Pubitemid 44118036)
13. Uversky VN, Dunker AK (2010) Understanding protein non-folding. Biochimica et biophysica acta 1804: 1231-1264.
14. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426: 905-909. (Pubitemid 38056884)
15. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, et al. (2000) Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 7: 312-321. (Pubitemid 30194456)
16. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, et al. (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America 109: 9629-9634.
17. Orwig SD, Tan YL, Grimster NP, Yu Z, Powers ET, et al. (2011) Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-beta-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Biochemistry 50: 10647-10657.
18. Metallo SJ (2010) Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol 14: 481-488.
19. Zhu M, De Simone A, Schenk D, Toth G, Dobson CM, et al. (2013) Identification of small-molecule binding pockets in the soluble monomeric form of the Abeta 42 peptide. The Journal of Chemical Physics 139: 035101.
20. McInnes C (2007) Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11: 494-502.
21. Vendruscolo M (2007) Determination of conformationally heterogeneous states of proteins. Curr Opin Struct Biol 17: 15-20.
22. Jensen MR, Markwick PR, Meier S, Griesinger C, Zweckstetter M, et al. (2009) Quantitative determination of the conformational properties of partially folded and intrinsically disordered proteins using NMR dipolar couplings. Structure 17: 1169-1185.
23. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, et al. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A 102: 1430-1435. (Pubitemid 40209187)
24. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. Journal of the American Chemical Society 127: 476-477. (Pubitemid 40174345)
25. Anwar S, Peters O, Millership S, Ninkina N, Doig N, et al. (2011) Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. The Journal of neuroscience: the official journal of the Society for Neuroscience 31: 7264-7274.
26. Auluck PK, Caraveo G, Lindquist S (2010) alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annual review of cell and developmental biology 26: 211-233.
27. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, et al. (2009) Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10: 218-234.
28. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. The Journal of neuroscience: the official journal of the Society for Neuroscience 22: 8797-8807.
29. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proceedings of the National Academy of Sciences of the United States of America 101: 14966-14971. (Pubitemid 39410782)
30. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324-328. (Pubitemid 44480951)
31. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, et al. (2012) Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta neuropathologica 123: 653-669.
32. Kim KS, Park JY, Jou I, Park SM (2010) Regulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells. The Journal of biological chemistry 285: 21416-21425.
33. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience 20: 3214-3220.
34. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
35. Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, et al. (2010) Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Disease models & mechanisms 3: 194-208.
36. Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, et al. (2010) Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Molecular biology of the cell 21: 1850-1863.
37. Westphal CH, Chandra SS (2013) Monomeric synucleins generate membrane curvature. The Journal of biological chemistry 288: 1829-1840.
38. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, et al. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329: 1663-1667.
39. Sudhof TC, Rizo J (2011) Synaptic vesicle exocytosis. Cold Spring Harbor perspectives in biology 3.
40. Palokangas H, Mulari M, Vaananen HK (1997) Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. Journal of cell science 110 (Pt 15): 1767-1780. (Pubitemid 27352856)
41. Hackam DJ, Rotstein OD, Sjolin C, Schreiber AD, Trimble WS, et al. (1998) v-SNARE-dependent secretion is required for phagocytosis. Proceedings of the National Academy of Sciences of the United States of America 95: 11691-11696. (Pubitemid 28460476)
42. Shyra J. Gardai WM, Birgitt Schüle, Michael Babcock, Sue Schoebel, Carlos Lorenzana, Jeff Alexander, Sam Kim, Heather Glick, Kathryn Hilton, J. Kent Fitzgerald, Manuel Buttini, San-San Chiou, Lisa McConlogue, John P Anderson, Dale B Schenk, Frederique Bard, J. William Langston, Ted Yednock,, and Jennifer A Johnston (2013) Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease. Plos One.
43. McGann M (2011) FRED pose prediction and virtual screening accuracy. Journal of chemical information and modeling 51: 578-596.
44. Kortvelyesi T, Dennis S, Silberstein M, Brown L, 3rd, Vajda S (2003) Algorithms for computational solvent mapping of proteins. Proteins 51: 340-351. (Pubitemid 36528820)
45. Landon MR, Lancia DR, Jr., Yu J, Thiel SC, Vajda S (2007) Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. Journal of medicinal chemistry 50: 1231-1240. (Pubitemid 46496323)
46. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35: 13709-13715. (Pubitemid 26363912)
47. Lendel C, Bertoncini CW, Cremades N, Waudby CA, Vendruscolo M, et al. (2009) On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and Lacmoid. Biochemistry 48: 8322-8334.
48. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, et al. (2002) Dependence of alpha-synuclein aggregate morphology on solution conditions. Journal of molecular biology 322: 383-393.
49. Uversky VN, Li J, Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276: 10737-10744. (Pubitemid 38089246)
50. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, et al. (2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Human molecular genetics 10: 1847-1851. (Pubitemid 32899100)
51. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of neurology 55: 164-173. (Pubitemid 38166992)
52. Liu J, Cavalli LR, Haddad BR, Papadopoulos V (2003) Molecular cloning, genomic organization, chromosomal mapping and subcellular localization of mouse PAP7: a PBR and PKA-RIalpha associated protein. Gene 308: 1-10. (Pubitemid 36597818)
53. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nature genetics 41: 308-315.
54. Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC (2008) Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. Journal of neurochemistry 105: 2435-2453. (Pubitemid 351782273)
55. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. The Journal of biological chemistry 281: 29739-29752. (Pubitemid 44536983)
56. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810. (Pubitemid 39434070)
57. Andersen PG (1982) Cox's regression model for counting processes, a large sample study. Annals of Statistics. 10: 1100-1120.
58. Allison JR, Varnai P, Dobson CM, Vendruscolo M (2009) Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. J Am Chem Soc 131: 18314-18326.
59. Salmon L, Nodet G, Ozenne V, Yin G, Jensen MR, et al. (2010) NMR characterization of long-range order in intrinsically disordered proteins. J Am Chem Soc 132: 8407-8418.
60. Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267: 383-386.
61. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America 97: 571-576. (Pubitemid 30070350)
62. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317: 516-519. (Pubitemid 47196116)
63. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, et al. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. The Journal of biological chemistry 286: 20710-20726.
64. Sharma P, Ando DM, Daub A, Kaye JA, Finkbeiner S (2012) High-throughput screening in primary neurons. Methods in enzymology 506: 331-360.
65. Chen J, Armstrong AH, Koehler AN, Hecht MH (2010) Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Abeta peptide and reduce its cytotoxicity. J Am Chem Soc 132: 17015-17022.
66. Bertoncini CW, Fernandez CO, Griesinger C, Jovin TM, Zweckstetter M (2005) Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. The Journal of biological chemistry 280: 30649-30652. (Pubitemid 41291792)
67. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-906. (Pubitemid 351149842)
68. Dobson CM (2003) Protein folding and misfolding. Nature 426: 884-890.